AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

PBH · NYSE · Medical - Pharmaceuticals

Prestige Consumer Healthcare (PBH)

Builds and markets an acquisition-led portfolio of OTC health and personal-care brands.

$47.73

After hours−0.03 (−0.06%)

At close$47.76(+2.05%)

In millions of USD, except per-share figures

In millions	Q2 FY24Sep 2023	Q3 FY24Dec 2023	Q4 FY24Mar 2024	Q1 FY25Jun 2024	Q2 FY25Sep 2024	Q3 FY25Dec 2024	Q4 FY25Mar 2025	Q1 FY26Jun 2025	Q2 FY26Sep 2025	Q3 FY26Dec 2025	Q4 FY26Mar 2026	Q1 FY27Jun 2026
Revenue	286	283	277	267	284	290	297	250	274	283	282	266
Cost of revenue	126	125	125	121	126	129	121	114	120	126	141	130
Gross profit	160	158	152	146	157	161	176	135	154	157	141	136
	72	71	70	74	73	69	87	63	74	75	65	84
	66	65	64	68	67	64	64	63	67	70	65	78
Selling & marketing	40	39	38	39	41	38	37	35	39	40	35	35
General & administrative	26	26	26	29	26	26	27	28	28	30	30	43
Other expenses	6	6	6	6	6	5	23	0	8	5	0	6
Operating income	88	87	82	72	84	92	88	72	80	82	75	53
	−18	−17	−15	−14	−13	−12	−14	−10	−11	−21	−11	−14
Interest expense	18	17	15	13	12	11	11	10	10	11	11	14
Other non-operating income	0	1	0	0	0	0	4	0	1	10	−1	0
Income before tax	70	70	67	58	72	80	74	62	69	62	65	39
Income tax expense	17	17	18	9	17	19	24	14	27	15	11	9
Net income from continuing operations	54	53	49	49	54	61	50	47	42	47	54	29
Net income	54	53	49	49	54	61	50	47	42	47	54	29
EPS, basic	$1.08	$1.07	$0.99	$0.98	$1.10	$1.23	$1.01	$0.96	$0.86	$0.98	$1.14	$0.61
EPS, diluted	$1.07	$1.06	$0.98	$0.98	$1.09	$1.22	$1.00	$0.95	$0.86	$0.97	$1.13	$0.61
Weighted average shares, basic	50	50	50	50	50	50	50	49	49	48	47	47
Weighted average shares, diluted	50	50	50	50	50	50	50	50	49	48	48	48
EBITDA	96	94	90	80	90	98	92	80	87	80	85	61
Depreciation & amortization	8	8	8	8	6	7	7	8	8	8	8	9
EBIT	88	86	83	72	84	92	85	72	79	72	76	52